Away from ASCO, handful of biotechs eye follow-ons or regularly submissions backed by new data

Plus: LianBio begins winding down, promises dividend; BioXcel pulls offering

What Gilead’s CD47 failure means for the class; KalVista to submit HAE program; Takeda advances narcolepsy therapy; and more

New data show NTLA-2002 nearly eliminates HAE attacks in first 10 patients

Plus: MinervaX taking strep vaccine to Phase II and updates from AbbVie, Prothena, Astria, Guardant and more

Plus Flagship’s Cellarity raises $121M series C and updates for Inhibrx, Autolus, Vir, Ginkgo and more 

The next test for Intellia will be whether it can achieve the same success with gene insertions

KalVista gained $17.89 (114%) to $33.50 on Tuesday after reporting its oral on-demand protease inhibitor for HAE attacks met its primary endpoint of reducing the use of rescue medication. 

Three months after its lone asset failed in Phase III testing, Catabasis Pharmaceuticals Inc. (NASDAQ:CATB) is acquiring Xontogeny portfolio company Quellis Biosciences Inc. and 

Takeda’s Andy Plump and Theravance’s Brett Haumann discuss the consortium’s priorities, and what lessons carry forward for 2021 and beyond